Exscientia (EXAI) said Wednesday it expects to receive in Q4 a total of $15 million in milestone payments after advancing two drug programs in its collaboration with Sanofi (SNY).
Exscientia said both compounds met the requirements set by both companies to enable a transition to an optimization phase in the collaboration.
The drug development company said it remains eligible to receive additional pre-commercial milestone payments of over $300 million and commercial milestones of over $300 million as well as tiered royalties as part of the Sanofi collaboration.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments